Epanova: Phase III data

The double-blind, U.S. Phase III ESPRIT trial in 647 patients with fasting triglyceride levels of 200-500 mg/dL showed that once-daily 2 and 4 g doses of Epanova as an add-on to statin therapy each met the primary endpoint of reducing non-HDL-C from baseline to week 6 vs. control (4 g olive oil) (4% and 7%, respectively, vs. 1%, p<0.05 and p<0.001). On secondary endpoints, low- and high-dose Epanova significantly reduced triglyceride levels from baseline to week 6 vs. control (15% and 21%, respectively, vs. 6%, p<0.001 for both). Both doses of Epanova non-significantly increased HDL-C by 3% vs. 2% for control. ...